Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study
- 1 November 2002
- journal article
- clinical trial
- Published by Elsevier in Clinical Therapeutics
- Vol. 24 (11) , 1871-1886
- https://doi.org/10.1016/s0149-2918(02)80085-6
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Tolerability of Once-Weekly Alendronate in Patients With Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled StudyMayo Clinic Proceedings, 2002
- Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive AgentsJournal of Clinical Endocrinology & Metabolism, 2002
- Alendronate for the Treatment of Osteoporosis in MenNew England Journal of Medicine, 2000
- Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone DensityJournal of Clinical Endocrinology & Metabolism, 2000
- Focus on Primary CareObstetrical & Gynecological Survey, 1999
- Issues in Patient ComplianceDrugs, 1997
- Patient compliance: recognition of factors involved and suggestions for promoting compliance with therapeutic regimensJournal of Advanced Nursing, 1996
- The Comparison of Success Rates in Cross-Over Trials in the Presence of an Order EffectJournal of the Royal Statistical Society Series C: Applied Statistics, 1981
- Strategies for enhancing patient complianceJournal of Community Health, 1980
- An exact test for comparing matched proportions in crossover designsBiometrika, 1969